Chen Highlights His Premium Silver, Gold Opportunities for Q2
Source: Streetwise Reports  (3/25/25)
Even with tariff chaos, asset manager Chen Lin of What is Chen Buying? What is Chen Selling? said he is still bullish in the near term for gold silver. Find out which stocks are his top picks for the coming quarter. More >

PDUFA Date Nearing for New PSVT Drug
Source: Patrick Trucchio  (3/19/25)
If approved, commercialization will start mid-year; the biopharma behind the treatment offers a potential return of 1,052%, noted an H.C. Wainwright & Co. report. More >

Two Use Cases for AI in Healthcare
Source: Streetwise Reports  (3/14/25)
In both, proprietary software platforms analyze heaps of data, but one focuses on genetics, the other neurology. Learn more about the companies behind the technology. More >

US$200M Deal Accelerates Phase 3 Gene Therapy for Parkinsons
Source: Streetwise Reports  (3/14/25)
MeiraGTx Holdings Plc.'s (MGTX:NASDAQ) partnership with Hologen AI secures US$200 million to advance its Phase 3 gene therapy for Parkinson's. With regulatory milestones ahead, here's what's next.

More >

Biotech Stock Looks Like Is Has a Great Set Up
Source: Clive Maund  (3/12/25)
Technical Analyst Clive Maund explains why he thinks Hemostemix Inc. (HEM:TSXV; HMTXF:OTCQB; 2VF0:FSE) is an Immediate Strong Buy. More >

Utah Biotech's Treatment Demonstrates Significant Survival Advantage for ALS Patients
Source: Jason Kolbert  (3/12/25)
Utah biotech Clene Inc. (CLNN:NASDAQ) recently shared new data, reporting the survival benefit of its CNM-Au8 treatment for ALS patients, according to a D. Boral Capital research note. More >

AI Study Tracks Unexpected Cognitive Gains in Vascular Dementia Trial
Source: Streetwise Reports  (3/11/25)
Hemostemix Inc.'s (HEM:TSXV; HMTXF:OTCQB; 2VF0:FSE) Phase 1 trial, in collaboration with Firefly Neuroscience Inc. (AIFF:NASDAQ), is evaluating ACP-01s impact on vascular dementia using AI-driven brain analysis. Early insights could reshape treatment approaches. More >

Biotech Advancing Pivotal Phase III Breast Cancer Trial
Source: Dr. Douglas Loe  (3/11/25)
Oncolytics Biotech Inc. (ONCY:NASDAQ; ONC:TSX) recently updated its timelines for the company's clinical testing, regulatory review, and potential commercial launch of its oncolytic reovirus formulation pelareorep in breast cancer, according to a report from Leede Financial Inc. More >

FDA OKs Trial of Cell Reservoir in Thyroid Disease
Source: Dr. Douglas Loe  (3/10/25)
In this Phase 1 study, post-thyroidectomy patients will be treated with their own thyroid cells via this implantable delivery device, noted a Leede Financial Inc. report. More >

With Competitor Out, New Drug Gains Edge in Chronic Cough
Source: Jason Kolbert  (3/10/25)
Phase 2b data, expected in H1/25, could support advancement of the therapeutic into late-stage development, noted a D. Boral Capital report. More >

New Drug for Major Depressive Disorder Gets Good Surprise
Source: Douglas Tsao  (3/10/25)
When a key competitor drops out, this treatment moves to top runner position; the biopharma behind it offers 1,084% upside, noted an H.C. Wainwright & Co. report. More >

Biotech Hits Critical Milestone for Cell-Pouch Bio-Hybrid Organ
Source: Streetwise Reports  (3/6/25)
Sernova Biotherapeutics Inc. (SVA:TSX.V; SEOVF:OTCQB; PSH:XETRA) announces that the FDA has cleared its investigational new drug (IND) application for its cell pouch with auto-transplanted thyroid cells in patients undergoing thyroid surgery for nodular thyroid disease. Find out why one analyst sees big returns coming from the stock. More >

Canadian Healthcare Co. Showcases Stable FQ424
Source: Dr. Douglas Loe  (3/6/25)
Leede Financial Inc. raised its target price on CareRX Corp. (CRRX:TSX; CHHHF:OTCMKTS). Read on to see why one Leede analyst rates the stock as a Buy. More >

Breakthrough ADHD Treatment Moves Closer to FDA Approval with New Data
Source: Streetwise Reports  (3/5/25)
Cingulate Inc.'s (CING:NASDAQ), latest Phase 3 data reinforces CTx-1301s potential as a true once-daily ADHD treatment. With an FDA meeting on the horizon, all eyes are on what's next. More >

Virtual Healthcare Breakthrough Expanding Access for 6.9M Medicaid Patients in New York
Source: Streetwise Reports  (2/27/25)
Rocket Doctor, under Treatment.com AI Inc. (TRUE:CSE; TREIF:OTCMKTS; 939:FRA), is now an in-network provider for New York Medicaid, expanding virtual healthcare access to 6.9 million beneficiaries. Find out how this milestone offers the possibility to reshape healthcare accessibility.

More >

DMT Study Set To Explore Breakthrough Potential in Stroke Recovery
Source: Streetwise Reports  (2/14/25)
Algernon Pharmaceuticals Inc. (AGN:CSE; AGNPF:OTCQB; AGW0:XFRA) subsidiary Algernon NeuroScience has appointed Dr. Sandor Nardai as Principal Investigator for its upcoming Phase 2a DMT stroke study. Find out how this trial could reshape stroke recovery research.

More >

Healthcare Tech Co. To Acquire Digital Health Platform
  (2/13/25)
This will expand its ecosystem of AI-powered products. Read on to learn more about its offerings and rapidly growing sector. More >

New Strategic Moves Aim To Accelerate Growth in AI Healthcare
Source: Streetwise Reports  (2/12/25)
Light AI Inc. (ALGO:CBOE) announces major marketing campaigns, advisory board appointments, and a key regulatory partnership to drive growth. Discover how these strategic moves could shape the future of AI healthcare.

More >

Kentucky Medical Co. Has Strong Operating Fundamentals
Source: Douglas Loe  (2/12/25)
Quipt Home Medical Corp. (QIPT:NASDAQ; QIPT:TSX.V) received a lowered price target but a Buy rating from a Leede Financial Inc. research note. More >

AI Stock in an Uptrend That Is Likely To Continue
Source: Clive Maund  (2/10/25)
Technical Analyst Clive Maund explains why he thinks Light AI Inc. (ALGO:CBOE) is an Immediate Strong Buy. More >

Healthcare Pioneer Expands Revolutionary Treatment Platform
Source: Streetwise Reports  (2/6/25)
Leading regenerative medicine company Sernova Biotherapeutics Inc. (SVA:TSX.V; SEOVF:OTCQB; PSH:XETRA) says it has submitted an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) for its Cell Pouch technology. One analyst says it is the "most advanced encapsulation device in development." More >

Biotech Requests OK to Assess Device in Second Indication
Source: Dr. Joseph Pantginis  (2/6/25)
The company behind this possible "pipeline in a device" wants to evaluate it now in thyroid disease after having begun with trials in type 1 diabetes, noted an H.C. Wainwright & Co. report. More >

Biotherapeutic Co. Offers Potential Curative Alternative For Thyroid Disease
Source: Douglas Lowe  (2/4/25)
Sernova Biotherapeutics Inc. (SVA:TSX.V; SEOVF:OTCQB; PSH:XETRA) recently filed a new IND for Cell Pouch in thyroid disease. Read on to see what rating and target price Leede Financial Inc. gave this company. More >

Washington D.C. Pharma Co. Receives FDA Acceptance
Source: Dr. Ram Selvaraju  (1/28/25)
Vanda Pharmaceuticals Inc. (VNDA:NASDAQ) recently received FDA acceptance of its request for a hearing regarding its tradipitant New Drug Application, reported an H.C. Wainwright & Co. analyst. More >

Biotech's Target Price 183.757% Higher Than Current
Source: Jason Kolbert  (1/24/25)
Read on to see why D. Boral Capital analyst Jason Kolbert gave IMUNON Inc. (IMNM:NASDAQ) a high target price. More >